News Releases

ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference

April 3, 2018

REDWOOD CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder, will participate in a panel presentation at the 8th Annual Cancer Immunotherapy Conference, taking place April 4-5 in New York City.

Presentation Details:
Date:   Wednesday, April 4 
Time:   11:35am Eastern Time 
Location:   Apella Event Space Alexandria Center, New York City 
Topic:   Cytokines 
Panelists:   Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder 
    ARMO BioSciences, Inc. 
    Deborah Charych, Ph.D., Executive Director of Research & Development 
    Nektar Therapeutics 

About the 8th Annual Cancer Immunotherapy Conference
Hosted by William Blair and MaidStone Life Sciences, the annual cancer immunotherapy conference is a unique, two-day conference that brings together the founding scientists, leading clinicians, and pioneering biopharmaceutical companies driving the field of cancer immunotherapy.  The agenda is designed to facilitate the exchange of information and highlight potential areas of opportunity for executives, investors, and others involved in transforming the future of cancer treatments.  Each day will consist of a series of presentations from leading experts across the various disciplines in immuno-oncology followed by panel discussions to further elucidate key issues and paths forward.

About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.  The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients.  ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).  For more information, please visit

ARMO BioSciences, Inc.
Herb Cross, Chief Financial Officer

Dan Ferry
LifeSci Advisors, LLC

Primary Logo

Source: ARMO BioSciences